Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01087294

Title field or adapter rule

{'original_value': 'Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.254590+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:11.341859+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Leukemia, B-cell", "Lymphoma, Hodgkins", "Lymphoma, Non-hodgkins", "Lymphoma, B-Cell"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT01087294"

protocolSection.identificationModule.officialTitle

"Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Leukemia, B-cell (protocolSection.conditionsModule.conditions)
• Lymphoma, Hodgkins (protocolSection.conditionsModule.conditions)
• Lymphoma, Non-hodgkins (protocolSection.conditionsModule.conditions)
• Lymphoma, B-Cell (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['1A/T cell Arm (closed)', '1B/T memory stem cell arm'], 'description': 'Allogeneic stem cell transplant', 'name': 'Allogeneic stem cell transplant', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['1A/T cell Arm (closed)', '1B/T memory stem cell arm'], 'description': 'Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.\n\nTWS119 is a glycogen synthase 3 inhibitor', 'name': 'Anti-CD19-chimeric-antigen-receptor-transduced T cells', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['2/Donor arm'], 'description': 'Donors will undergo leukapheresis', 'name': 'Leukapheresis', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.